{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:51:23Z","timestamp":1785372683437,"version":"3.55.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":142,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018942","name":"Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Alzheimer's disease is a multifaceted neurodegenerative disorder, with diverse underlying pathophysiological processes extending beyond amyloid-\u03b2 and tau accumulation. The heterogeneity of Alzheimer's disease necessitates the identification of a broad array of biomarkers that capture the diverse mechanisms contributing to disease onset and progression. In this study, we systematically compiled and analysed cerebrospinal fluid proteomics data from omics studies utilizing mass spectrometry, Olink, or SomaScan platforms. Systematic literature searches for each platform revealed a total of 264 studies. From this, a set of 18 studies were selected based on sample size, number of markers analysed, and open data availability. We found a total of 1,448 differentially expressed proteins between Alzheimer's disease and amyloid negative controls across these datasets, with 635 being found in more than one study. A \u2018top\u2019 set of 61 differentially expressed proteins were consistently reported in at least six studies. Clustering and functional enrichment analysis of the top differentially expressed proteins indicated involvement in metabolic regulation, glutathione metabolism and proteins of the 14-3-3 family, reflecting importance of reactive oxygen species (ROS) response. Synaptic signalling processes were found to generally be downregulated. We further integrated the top differentially expressed proteins with results from a study on familial Alzheimer's disease cerebrospinal fluid to assess at which stage of disease progression these proteins change, highlighting markers shared between sporadic and familial Alzheimer's disease datasets. Lastly, we examine the overlap of the top differentially expressed proteins between cerebrospinal fluid and brain tissue using a publicly available database. This analysis provides a comprehensive overview of the Alzheimer's disease cerebrospinal fluid proteomic landscape, indicating changes in key pathways and cellular processes associated with Alzheimer's disease pathology. By integrating data from different platforms, we highlight reproducible protein changes that may serve as promising candidates for further biomarker research aimed at improving patient stratification, tracking disease progression, and assessing therapeutic interventions.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf202","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:57:09Z","timestamp":1748023029000},"source":"Crossref","is-referenced-by-count":6,"title":["A compilation of reported alterations in the cerebrospinal fluid proteome in Alzheimer's disease"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-9393","authenticated-orcid":false,"given":"Matthijs B","family":"de Geus","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]},{"name":"Cell & Chemical Biology, Leiden University Medical Center , 2333ZC Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus C","family":"Nairn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry , Yale University, New Haven, CT 06511 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital , Charlestown, MA 02129 ,","place":["USA"]},{"name":"Neurology, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1491-3217","authenticated-orcid":false,"given":"Becky C","family":"Carlyle","sequence":"additional","affiliation":[{"name":"Department of Physiology Anatomy and Genetics, Oxford University , Oxford OX1 3PT ,","place":["UK"]},{"name":"Kavli Institute for Nanoscience Discovery , Oxford OX1 3QU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"6","key":"2025060900213974900_fcaf202-B1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.tins.2023.03.005","article-title":"Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer\u2019s disease","volume":"46","author":"Young-Pearse","year":"2023","journal-title":"Trends Neurosci"},{"issue":"1","key":"2025060900213974900_fcaf202-B2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","article-title":"Heterogeneity in Alzheimer\u2019s disease diagnosis and progression rates: Implications for therapeutic trials","volume":"19","author":"Duara","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2025060900213974900_fcaf202-B3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"issue":"8","key":"2025060900213974900_fcaf202-B4","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","article-title":"Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease","volume":"29","author":"Johnson","year":"2023","journal-title":"Nat Med"},{"issue":"7\u20138","key":"2025060900213974900_fcaf202-B5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/prca.201400178","article-title":"Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer\u2019s disease neuroimaging initiative (ADNI) CSF","volume":"9","author":"Spellman","year":"2015","journal-title":"Proteomics Clin Appl"},{"issue":"1","key":"2025060900213974900_fcaf202-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0397-4","article-title":"Alzheimer disease pathology and the cerebrospinal fluid proteome","volume":"10","author":"Dayon","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2025060900213974900_fcaf202-B7","doi-asserted-by":"crossref","first-page":"e1800105","DOI":"10.1002\/prca.201800105","article-title":"Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer\u2019s disease","volume":"13","author":"Sathe","year":"2019","journal-title":"Proteomics Clin Appl"},{"issue":"6","key":"2025060900213974900_fcaf202-B8","doi-asserted-by":"crossref","first-page":"e9356","DOI":"10.15252\/msb.20199356","article-title":"Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer\u2019s disease","volume":"16","author":"Bader","year":"2020","journal-title":"Mol Syst Biol"},{"issue":"43","key":"2025060900213974900_fcaf202-B9","doi-asserted-by":"crossref","first-page":"eaaz9360","DOI":"10.1126\/sciadv.aaz9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease","volume":"6","author":"Higginbotham","year":"2020","journal-title":"Sci Adv"},{"issue":"6","key":"2025060900213974900_fcaf202-B10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.neuron.2019.12.015","article-title":"Deep multilayer brain proteomics identifies molecular networks in Alzheimer\u2019s disease progression","volume":"105","author":"Bai","year":"2020","journal-title":"Neuron"},{"issue":"5","key":"2025060900213974900_fcaf202-B11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","article-title":"Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation","volume":"26","author":"Johnson","year":"2020","journal-title":"Nat Med."},{"issue":"1","key":"2025060900213974900_fcaf202-B12","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.1038\/s41598-020-64461-y","article-title":"SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer\u2019s disease","volume":"10","author":"Park","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"2025060900213974900_fcaf202-B13","doi-asserted-by":"crossref","first-page":"22406","DOI":"10.1038\/s41598-023-49440-3","article-title":"Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer\u2019s disease in a large clinical sample","volume":"13","author":"de Geus","year":"2023","journal-title":"Sci Rep."},{"issue":"712","key":"2025060900213974900_fcaf202-B14","doi-asserted-by":"crossref","first-page":"eadg4122","DOI":"10.1126\/scitranslmed.adg4122","article-title":"A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer\u2019s disease","volume":"15","author":"Haque","year":"2023","journal-title":"Sci Transl Med"},{"issue":"18","key":"2025060900213974900_fcaf202-B15","doi-asserted-by":"crossref","first-page":"14225","DOI":"10.3390\/ijms241814225","article-title":"Identification of candidate biomarkers of Alzheimer\u2019s disease via multiplex cerebrospinal fluid and serum proteomics","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025060900213974900_fcaf202-B16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-023-00638-z","article-title":"Quantitative proteomics of cerebrospinal fluid from African Americans and caucasians reveals shared and divergent changes in Alzheimer\u2019s disease","volume":"18","author":"Modeste","year":"2023","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2025060900213974900_fcaf202-B17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41597-023-02158-3","article-title":"Quantitative mass spectrometry analysis of cerebrospinal fluid protein biomarkers in Alzheimer\u2019s disease","volume":"10","author":"Watson","year":"2023","journal-title":"Sci Data"},{"issue":"1","key":"2025060900213974900_fcaf202-B18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","article-title":"Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles","volume":"4","author":"Tijms","year":"2024","journal-title":"Nat Aging"},{"issue":"7","key":"2025060900213974900_fcaf202-B19","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.mcpro.2023.100577","article-title":"MS-based proteomics of body fluids: The end of the beginning","volume":"22","author":"Bader","year":"2023","journal-title":"Mol Cell Proteomics."},{"issue":"1","key":"2025060900213974900_fcaf202-B20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13024-021-00474-z","article-title":"Proteomic landscape of Alzheimer\u2019s disease: Novel insights into pathogenesis and biomarker discovery","volume":"16","author":"Bai","year":"2021","journal-title":"Mol Neurodegener."},{"issue":"1","key":"2025060900213974900_fcaf202-B21","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1038\/s41467-023-41122-y","article-title":"CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u2019s disease","volume":"14","author":"del Campo","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"2025060900213974900_fcaf202-B22","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41593-024-01737-w","article-title":"Proteomic changes in Alzheimer\u2019s disease associated with progressive A\u03b2 plaque and tau tangle pathologies","volume":"27","author":"Pichet Binette","year":"2024","journal-title":"Nat Neurosci"},{"issue":"7","key":"2025060900213974900_fcaf202-B23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/biom13071094","article-title":"Exploratory assessment of proteomic network changes in cerebrospinal fluid of mild cognitive impairment patients: A pilot study","volume":"13","author":"Kamalian","year":"2023","journal-title":"Biomolecules"},{"issue":"10","key":"2025060900213974900_fcaf202-B24","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41562-024-01924-6","article-title":"Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer\u2019s disease","volume":"8","author":"Guo","year":"2024","journal-title":"Nat Hum Behav"},{"key":"2025060900213974900_fcaf202-B25","doi-asserted-by":"crossref","first-page":"100168","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","volume":"20","author":"Wik","year":"2021","journal-title":"Mol Cell Proteomics"},{"issue":"12","key":"2025060900213974900_fcaf202-B26","doi-asserted-by":"crossref","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"2025060900213974900_fcaf202-B27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","article-title":"Multi-platform proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome","volume":"14","author":"Dammer","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2025060900213974900_fcaf202-B28","doi-asserted-by":"crossref","first-page":"101005","DOI":"10.1016\/j.xcrm.2023.101005","article-title":"Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer\u2019s disease biomarkers","volume":"4","author":"van Zalm","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"2025060900213974900_fcaf202-B29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12014-020-09276-9","article-title":"A comprehensive systematic review of CSF proteins and peptides that define Alzheimer\u2019s disease","volume":"17","author":"Pedrero-Prieto","year":"2020","journal-title":"Clin Proteomics"},{"issue":"11","key":"2025060900213974900_fcaf202-B30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/14789450.2017.1384697","article-title":"Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: An update","volume":"14","author":"Portelius","year":"2017","journal-title":"Expert Rev Proteomics"},{"issue":"D1","key":"2025060900213974900_fcaf202-B31","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2025060900213974900_fcaf202-B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40208-x","article-title":"Compilation of reported protein changes in the brain in Alzheimer's disease.","volume":"14","author":"Askenazi","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2025060900213974900_fcaf202-B33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/alz.12612","article-title":"Potential role of chitinase-3-like protein 1 (CHI3L1\/YKL-40) in neurodegeneration and Alzheimer\u2019s disease","volume":"19","author":"Connolly","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2025060900213974900_fcaf202-B34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00401-024-02819-6","article-title":"SMOC1 colocalizes with Alzheimer\u2019s disease neuropathology and delays A\u03b2 aggregation","volume":"148","author":"Balcomb","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2025060900213974900_fcaf202-B35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13195-023-01269-8","article-title":"Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer\u2019s disease continuum","volume":"15","author":"Paciotti","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"17","key":"2025060900213974900_fcaf202-B36","doi-asserted-by":"crossref","first-page":"9540","DOI":"10.3390\/ijms23179540","article-title":"Dysfunctional glucose metabolism in Alzheimer\u2019s disease onset and potential pharmacological interventions","volume":"23","author":"Kumar","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025060900213974900_fcaf202-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0512-1","article-title":"FDG-PET as an independent biomarker for Alzheimer\u2019s biological diagnosis: A longitudinal study","volume":"11","author":"Ou","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"2025060900213974900_fcaf202-B38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbadis.2011.10.003","article-title":"Elevation of glutathione as a therapeutic strategy in Alzheimer disease","volume":"1822","author":"Pocernich","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"S5","key":"2025060900213974900_fcaf202-B39","doi-asserted-by":"crossref","first-page":"e054228","DOI":"10.1002\/alz.054228","article-title":"Altered central and peripheral glutathione in Alzheimer disease and mild cognitive impairment: A meta-analysis","volume":"17","author":"Chen","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2025060900213974900_fcaf202-B40","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.biopsych.2015.04.005","article-title":"Brain glutathione levels\u2014A novel biomarker for mild cognitive impairment and Alzheimer\u2019s disease","volume":"78","author":"Mandal","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2025060900213974900_fcaf202-B41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3233\/JAD-132483","article-title":"The emerging role of glutathione in Alzheimer\u2019s disease","volume":"40","author":"Saharan","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2025060900213974900_fcaf202-B42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.9758\/cpn.23.1053","article-title":"A preliminary study on the potential protective role of the antioxidative stress markers of cognitive impairment: Glutathione and glutathione reductase","volume":"21","author":"Park","year":"2023","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2025060900213974900_fcaf202-B43","author":"Saul"},{"issue":"6","key":"2025060900213974900_fcaf202-B44","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/antiox11061075","article-title":"Dipeptide of \u03c8-GSH inhibits oxidative stress and neuroinflammation in an Alzheimer\u2019s disease mouse model","volume":"11","author":"Raza","year":"2022","journal-title":"Antioxidants"},{"key":"2025060900213974900_fcaf202-B45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2022.03.021","article-title":"A quantitative proteomic analysis reveals the potential roles of PRDX3 in neurite outgrowth in N2a-APPswe cells","volume":"604","author":"Xu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"2025060900213974900_fcaf202-B46","doi-asserted-by":"crossref","first-page":"651105","DOI":"10.3389\/fphys.2021.651105","article-title":"Thioredoxin-1 is a target to attenuate Alzheimer-like pathology in diabetic encephalopathy by alleviating endoplasmic reticulum stress and oxidative stress","volume":"12","author":"Guo","year":"2021","journal-title":"Front Physiol"},{"key":"2025060900213974900_fcaf202-B47","doi-asserted-by":"crossref","first-page":"1016071","DOI":"10.3389\/fmolb.2022.1016071","article-title":"Structural insights into the functional roles of 14-3-3 proteins","volume":"9","author":"Obsilova","year":"2022","journal-title":"Front Mol Biosci"},{"key":"2025060900213974900_fcaf202-B48","doi-asserted-by":"crossref","first-page":"1286536","DOI":"10.3389\/fmolb.2024.1286536","article-title":"14-3-3 proteins\u2014A moonlight protein complex with therapeutic potential in neurological disorder: In-depth review with Alzheimer\u2019s disease","volume":"11","author":"Abdi","year":"2024","journal-title":"Front Mol Biosci"},{"issue":"4","key":"2025060900213974900_fcaf202-B49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tips.2021.01.001","article-title":"14-3-3 proteins: Novel pharmacological targets in neurodegenerative diseases","volume":"42","author":"Pair","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"2025060900213974900_fcaf202-B50","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/alz.12353","article-title":"Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer\u2019s disease","volume":"17","author":"Libiger","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2025060900213974900_fcaf202-B51","doi-asserted-by":"crossref","first-page":"e0135365","DOI":"10.1371\/journal.pone.0135365","article-title":"High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer\u2019s disease in human cerebrospinal fluid","volume":"10","author":"Hendrickson","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"2025060900213974900_fcaf202-B52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00702-021-02411-2","article-title":"Neuronal pentraxins as biomarkers of synaptic activity: From physiological functions to pathological changes in neurodegeneration","volume":"129","author":"G\u00f3mez de San Jos\u00e9","year":"2022","journal-title":"J Neural Transm"},{"issue":"2","key":"2025060900213974900_fcaf202-B53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/mds.29287","article-title":"Cerebrospinal fluid biomarkers of synaptic dysfunction are altered in Parkinson\u2019s disease and related disorders","volume":"38","author":"Nilsson","year":"2023","journal-title":"Mov Disord"},{"issue":"4","key":"2025060900213974900_fcaf202-B54","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ana.26725","article-title":"NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to mild cognitive impairment","volume":"94","author":"Soldan","year":"2023","journal-title":"Ann Neurol"},{"key":"2025060900213974900_fcaf202-B55","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.12688\/f1000research.15095.1","article-title":"Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer\u2019s disease progression","volume":"7","author":"Begcevic","year":"2018","journal-title":"F1000Res"},{"issue":"1","key":"2025060900213974900_fcaf202-B56","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1038\/s41467-020-17405-z","article-title":"Multiscale causal networks identify VGF as a key regulator of Alzheimer\u2019s disease","volume":"11","author":"Beckmann","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"2025060900213974900_fcaf202-B57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-017-0335-x","article-title":"Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease","volume":"10","author":"Duits","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2025060900213974900_fcaf202-B58","doi-asserted-by":"crossref","first-page":"fcab261","DOI":"10.1093\/braincomms\/fcab261","article-title":"VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases","volume":"3","author":"Quinn","year":"2021","journal-title":"Brain Commun"},{"issue":"3","key":"2025060900213974900_fcaf202-B59","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1460-9568.1998.00121.x","article-title":"Synaptic loss reflected by secretoneurin-like immunoreactivity in the human hippocampus in Alzheimer\u2019s disease","volume":"10","author":"Kaufmann","year":"1998","journal-title":"Eur J Neurosci."},{"issue":"1","key":"2025060900213974900_fcaf202-B60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1172\/JCI32723","article-title":"Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2\/Stat3 pathway in murine models of stroke","volume":"118","author":"Shyu","year":"2008","journal-title":"J Clin Invest."},{"issue":"4","key":"2025060900213974900_fcaf202-B61","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/jasms.2c00341","article-title":"Cerebrospinal fluid and brain proteoforms of the granin neuropeptide family in Alzheimer\u2019s disease","volume":"34","author":"Quinn","year":"2023","journal-title":"J Am Soc Mass Spectrom"},{"issue":"1","key":"2025060900213974900_fcaf202-B62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-022-00521-3","article-title":"Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer\u2019s disease","volume":"17","author":"Visser","year":"2022","journal-title":"Mol Neurodegener."},{"issue":"21","key":"2025060900213974900_fcaf202-B63","doi-asserted-by":"crossref","first-page":"12841","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"S12","key":"2025060900213974900_fcaf202-B64","doi-asserted-by":"crossref","first-page":"e079106","DOI":"10.1002\/alz.079106","article-title":"The SMOC1-matrisomal proteomics network M42 controls brain homeostasis and modulates toxicity in fly Alzheimer\u2019s disease models","volume":"19","author":"Li-Kroeger","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2025060900213974900_fcaf202-B65","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease","volume":"68","author":"Craig-Schapiro","year":"2010","journal-title":"Biol Psychiatry"},{"issue":"1","key":"2025060900213974900_fcaf202-B66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-023-01131-9","article-title":"Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer","volume":"56","author":"Yu","year":"2024","journal-title":"Exp Mol Med"},{"issue":"1","key":"2025060900213974900_fcaf202-B67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13073-023-01155-w","article-title":"The neuroimmune axis of Alzheimer\u2019s disease","volume":"15","author":"Jorfi","year":"2023","journal-title":"Genome Med"},{"key":"2025060900213974900_fcaf202-B68","doi-asserted-by":"crossref","first-page":"101409","DOI":"10.1016\/j.arr.2021.101409","article-title":"The role of the immune system in Alzheimer\u2019s disease","volume":"70","author":"Wu","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"369","key":"2025060900213974900_fcaf202-B69","doi-asserted-by":"crossref","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","article-title":"Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury","volume":"8","author":"Su\u00e1rez-Calvet","year":"2016","journal-title":"Sci Transl Med"},{"issue":"14","key":"2025060900213974900_fcaf202-B70","doi-asserted-by":"crossref","first-page":"eadk3674","DOI":"10.1126\/sciadv.adk3674","article-title":"CSF biomarkers of immune activation and Alzheimer\u2019s disease for predicting cognitive impairment risk in the elderly","volume":"10","author":"Shue","year":"2024","journal-title":"Sci Adv"},{"issue":"1","key":"2025060900213974900_fcaf202-B71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","article-title":"Neurogranin and YKL-40: Independent markers of synaptic degeneration and neuroinflammation in Alzheimer\u2019s disease","volume":"7","author":"Hellwig","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2025060900213974900_fcaf202-B72","doi-asserted-by":"crossref","first-page":"100731","DOI":"10.1016\/j.mcpro.2024.100731","article-title":"The importance, challenges, and possible solutions for sharing proteomics data while safeguarding individuals\u2019 privacy","volume":"23","author":"Shome","year":"2024","journal-title":"Mol Cell Proteomics"},{"key":"2025060900213974900_fcaf202-B73","first-page":"123","article-title":"Alzheimer\u2019s disease\u2014Why we need early diagnosis","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Degener Neurol Neuromuscul Dis"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf202\/63313205\/fcaf202.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/3\/fcaf202\/63313205\/fcaf202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/3\/fcaf202\/63313205\/fcaf202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T04:21:58Z","timestamp":1749442918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf202\/8142579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf202","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf202"}}